Skip to main content
. 2013 Apr 18;304(12):G1103–G1116. doi: 10.1152/ajpgi.00299.2012

Fig. 7.

Fig. 7.

Dynamic control of ZSCAN4 expression in chronic pancreatitis under inflammation and regeneration. ZSCAN4 expression patterns in tissues taken from patients with chronic alcoholic pancreatitis and autoimmune pancreatitis. A: a representative ZSCAN4 immunostaining of the pancreas from an unaffected individual. Arrow, a ZSCAN4+ cell. B: a representative ZSCAN4 immunostaining of the pancreas from a patient with chronic alcoholic pancreatitis. ZSCAN4+ cells are scattered in the pancreas. A number of ZSCAN4+ cells in the islet of Langerhans are dramatically increased in sections of alcoholic pancreatitis. C: a representative ZSCAN4 immunostaining of the duct region of the pancreas from a patient with untreated autoimmune pancreatitis. ZSCAN4+ cells increase in tissues on chronic inflammation. Arrows, a small-sized pancreatic duct containing a few ZSCAN4+ cells. D: a representative ZSCAN4 immunostaining of the acinar region of the pancreas from a patient with untreated autoimmune pancreatitis. ZSCAN4+ cells are scattered throughout the pancreas with autoimmune pancreatitis. E: a representative ZSCAN4 immunostaining of the pancreas from a patient with autoimmune pancreatitis under the maintenance corticosteroid therapy for 3 mo. A large number of ZSCAN4+ cells are seen in pancreatic ducts, the islet of Langerhans, and regenerating pancreatic acinar cells. F: a representative ZSCAN4 immunostaining of the pancreas from a patient with autoimmune pancreatitis under the maintenance corticosteroid therapy for 12 mo. Note that immunoreactivity for ZSCAN4 almost disappeared and returned to a basal level at fully regenerated tissues. G: the no. of ZSCAN4+ cells per high-power field (HPF) in each condition is summarized (n = 3–5, mean ± SD). Normal subjects, 1.8 ± 1.3; alcoholic pancreatitis (AL-CP), 118.8 ± 97.0; autoimmune pancreatitis pretreatment (AIP pre), 193.0 ± 56.0; autoimmune pancreatitis 3 mo after the initiation of corticosteroid treatment (AIP 3m Tx), 208.7 ± 23.4; autoimmune pancreatitis 1 yr after the initiation of corticosteroid treatment (AIP 1y Tx), 0.6 ± 0.9. *P < 0.01 and **P < 0.05.